Abstract Objective To evaluate the preliminary clinical efficacy of bevacizumab for cerebral radiation necrosis (CRN). Methods Nineteen patients with CRN for whom the treatment with steroids and mannitol failed were retrospectively analyzed with a total of 22 lesions. Except for 5 lesions confirmed by pathological evidence, all lesions were confirmed by the following imaging evidence:1. computed tomography (CT)-or magnetic resonance imaging (MRI)-enhanced lesions showed loss of tension and were accompanied by substantial edema;2. CT-or MRI-enhanced lesions had a low perfusion pressure;3. magnetic resonance spectroscopy indicated that the enhanced areas had a decreased choline peak;4. positron emission tomography showed that the fluorodeoxyglucose uptake was substantially reduced in the enhanced areas. All patients were given 5 mg/kg bevacizumab at an interval of 14 days for 2-6 cycles. MRI examination was performed in each cycle before treatment, and the enhanced lesions on T1-weighted images (T1WI) and edema on T2-weighted images (T2WI) were compared before and after treatment. The clinical symptoms, Karnofsky Performance Status (KPS), and adverse reactions in all patients were evaluated. Comparison before and after treatment was performed by paired t test. Results All 19 patients completed the treatment successfully and there were no severe adverse reactions. The clinical symptoms of patients were substantially improved after the second cycle of treatment, and the KPS score increased by 26.8 on average. The visible volume of enhanced lesions on MRI T1WI was significantly reduced by 54.8% after treatment (P=0.000), while the visible volume of edema on MRI T2WI was reduced by 80.7% after treatment (P=0.000). The follow-up time ranged from 3 to 12 months with a mean value of 5.6 months. Eleven patients kept clinical improvement in CRN, four patients had recurrence, and four patients died from tumor progression. Conclusions Bevacizumab is preliminarily confirmed to substantially improve the clinical symptoms and quality of life in patients with CRN.
Pan Mianshun,Li Yong,Qiu Shujun et al. Preliminary efficacy of bevacizumab for cerebral radiation necrosis[J]. Chinese Journal of Radiation Oncology, 2015, 24(4): 434-437.
Pan Mianshun,Li Yong,Qiu Shujun et al. Preliminary efficacy of bevacizumab for cerebral radiation necrosis[J]. Chinese Journal of Radiation Oncology, 2015, 24(4): 434-437.
[1] 潘绵顺,王鹏,蒋华平,等.放射性脑损伤及相关问题[J].立体定向和功能性神经外科杂志,2007,20(3):187-191. [2] Jiang S, Xia R, Jiang Y,et al. Vascular endothelial growth factors enhance the permeability of the mouse blood-brain barrier[J/OL].PLoS One,2014,9(2):e86407[2015-02-10].http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3925082/.DOI:10.1371/journal.pone.0086407. [3] Schmid S, Aboul-Enein F, Pfisterer W,et al. Vascular endothelial growth factor:the major factor for tumor neovascularization and edema formation in meningioma patients[J].Neurosurgery,2010,67(6):1703-1708.DOI:10.1227/NEU.0b013e3181fb801b. [4] Greene-Schloesser D,Robbins ME,Peiffer AM,et al. Radiation-induced brain injury:a review[J].Front Oncol,2012,2:73.DOI:10.3389/fonc.2012.00073. [5] Chao ST, Ahluwalia MS, Barnett GH, et al. Challenges with the diagnosis and treatment of cerebral radiation necrosis[J]. Int J Radiat Oncol Biol Phys,2013,87(3):449-57.DOI:10.1016/j.ijrobp.2013.05.015. [6] Wang YX, King AD, Zhou H,et al. Evolution of radiation-induced brain injury:MR imaging-based study[J]. Radiology,2010,254(1):210-218.DOI:10.1148/radiol.09090428. [7] Minniti G, Clarke E, Lanzetta G, et al. Stereotactic radiosurgery for brainmetastases:analysis of outcome and risk of brain radionecrosis[J].Radiat Oncol,2011,6:48.DOI:10.1186/1748-717X-6-48. [8] Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low-versus high-dose radiation therapy in adults with supratentorial low-grade glioma:initial report of a north central cancer treatment group/radiation therapy oncology group/eastern cooperative oncology group study[J].J Clin Oncol,2002,20(9):2267-2276. [9] Chin LS, Ma L, DiBiase S. Radiation necrosis following gamma knife surgery:a case-controlled comparison of treatment parameters and long-term clinical follow up[J].J Neurosurg,2001,94(6):899-904. [10] Minniti G, Clarke E, Lanzetta G, et al. Stereotactic radiosurgery for brain metastases:analysis of outcome and risk of brain radionecrosis[J/OL]. Radiat Oncol,2011,6:48[2015-02-10].http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108308/.DOI:10.1186/1748-717X-6-48. [11] Truong MT, St Clair EG, Donahue BR, et al. Results of surgical resection for progression of brain metastases previously treated by gamma knife radiosurgery[J].Neurosurgery,2006,59(1):86-97. [12] Stewart MW. Anti-VEGF therapy for diabetic macular edema[J/OL].Curr Diab Rep,2014,14(8):510[2015-02-10].http://link.springer.com/article/10.1007%2Fs11892-014-0510-4.DOI:10.1007/s11892-014-0510-4. [13] Gonzalez J, Kumar AJ, Conrad CA, et al. Effect of bevacizumab on radiation necrosis of the brain[J]. Int J Radiat Oncol Biol Phys,2007,67(2):323-326. [14] Levin VA, Bidaut L, Hou P,et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system[J]. Int J Radiat Oncol Biol Phys,2011,79(5):1487-1495.DOI:10.1016/j.ijrobp.2009.12.061. [15] Boothe D, Young R, Yamada Y,et al. Bevacizumab as a treatment for radiation necrosis of brain metastases post stereotactic radiosurgery[J].Neuro Oncol,2013,15(9):1257-1263.DOI:10.1093/neuonc/not085. [16] Wang Y, Pan L, Sheng X,et al. Reversal of cerebral radiation necrosis with bevacizumab treatment in 17 Chinese patients[J/OL].Eur J Med Res,2012,17:25[2015-02-10].http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493338/.DOI:10.1186/2047-783X-17-25.
2015, Vol. 24 
